Skip to main content

Paul Langlie Martin, MD, PhD

Professor of Pediatrics
Chief, Division of Pediatric Blood and Marrow Transplantation
Member of the Duke Cancer Institute
Campus mail: 1400 Morrene Rd, Durham, NC 27705
Phone: (919) 668-1124
Email address: paul.martin@duke.edu

For most of my career in Pediatric Hematology/Oncology I have focused on the use of stem cell transplant for the treatment of pediatric leukemias (ALL, AML, CML and JMML) and other non-malignant blood disorders, such as thalassemia, hemaphagocytic disorders, Wiskott-Aldrich, aplastic anemia, Diamond-Blackfan Anemia, as well as inherited metabolic diseases. In addition to focusing on determining the best use of stem cell transplants for these disorders, I have also been involved in clinical research investigating the prevention and treatment of transplant related morbidity, particularly veno-occlusive disease of the liver, infections and diffuse alveolar hemorrhage. As study chair for the Children's Oncology Group protocol 9904, I was involved in the development, implementation and analysis of a large, international frontline study of childhood acute lymphoblastic leukemia. Results from this study show that a significant number of children with certain favorable cytogenetic abnormalities in their leukemic cells and who have a rapid response to their initial chemotherapy can expect to have a >95% chance of cure when treated with relatively low intensity chemotherapy.  

For most of my time at Duke I have concentrated on providing high quality care for high risk leukemia patients who require high intensity therapies, such as stem cell transplant and immunotherapy.  As a member of the Pediatric Transplant and Cellular Therapy Division I provide clinical care for these patients.  As a member of various cooperative groups and local PI for several drug trials, I have worked to provide better care and more specific therapies for the toxicities associated with stem cell transplant.  

I have also collaborated with the Pediatric Immunology Division to provide a life-saving therapy for a small group of patients with thymic dysfunction, which causes severe immunodeficiency.  Our clinical team now provides support during these patients hospital admissions for donor thymus tissue implantation.

Education and Training

  • Fellow, Pediatric Hematology/Oncology, Pediatrics, Yale University, 1989 - 1992
  • Resident, Pediatrics, Yale University, 1988 - 1989
  • Intern, Pediatrics, Yale University, 1987 - 1988
  • Ph.D., Washington University in St. Louis, 1987
  • M.D., Washington University in St. Louis, 1987

Publications

Wainwright, M. S., P. L. Martin, R. P. Morse, M. Lacaze, J. M. Provenzale, R. E. Coleman, M. A. Morgan, et al. “Human herpesvirus 6 limbic encephalitis after stem cell transplantation.” Ann Neurol 50, no. 5 (November 2001): 612–19. https://doi.org/10.1002/ana.1251.

Full Text

Barker, J. N., P. L. Martin, J. E. Coad, T. DeFor, M. E. Trigg, J. Kurtzberg, D. J. Weisdorf, and J. Wagner. “Low incidence of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorders in 272 unrelated-donor umbilical cord blood transplant recipients.” Biol Blood Marrow Transplant 7, no. 7 (2001): 395–99. https://doi.org/10.1053/bbmt.2001.v7.pm11529490.

Full Text

Safford, S. D., K. M. Safford, P. Martin, H. Rice, J. Kurtzberg, and M. A. Skinner. “Management of cholelithiasis in pediatric patients who undergo bone marrow transplantation.” J Pediatr Surg 36, no. 1 (January 2001): 86–90. https://doi.org/10.1053/jpsu.2001.20016.

Full Text

Howrey, R. P., P. L. Martin, T. Driscoll, P. Szabolcs, T. Kelly, E. J. Shpall, S. I. Bearman, et al. “Graft-versus-leukemia-induced complete remission following unrelated umbilical cord blood transplantation for acute leukemia.” Bone Marrow Transplant 26, no. 11 (December 2000): 1251–54. https://doi.org/10.1038/sj.bmt.1702697.

Full Text

Kurtzberg, J., P. Szabolcs, R. P. Howrey, T. A. Driscoll, and P. L. Martin. “High dose chemotherapy followed by transplantation of unrelated, banked, umbilical cord blood provides curative therapy for young pediatric patients with familial erythrophagocytic lymphohistiocytosis fed.” Blood 96, no. 11 PART II (December 1, 2000).

Scholars@Duke

Kurtzberg, J., P. L. Martin, and P. M. Szabolcs. “Outcomes of unrelated umbilical cord blood transplantation in 158 pediatric patients consecutively transplanted at a single institution using cord blood units from a single bank.” Blood 96, no. 11 PART I (December 1, 2000).

Scholars@Duke

Martin, P. L., and M. Lacaze. “Unrelated umbilical cord blood transplant for osteopetrosis.” Blood 96, no. 11 PART I (December 1, 2000).

Scholars@Duke

Kurtzberg, J., P. Szabolcs, R. P. Howrey, T. A. Driscoll, and P. L. Martin. “High dose chemotherapy followed by transplantation of unrelated, banked, umbilical cord blood provides curative therapy for young pediatric patients with familial erythrophagocytic lymphohistiocytosis (FEL).” Blood 96, no. 11 (November 16, 2000): 362B-362B.

Scholars@Duke

Barker, J. N., P. L. Martin, T. Defor, D. J. Weisdorf, J. Kurtzberg, and J. E. Wagner. “Low incidence of Epstein-Barr virus-associated post-transplant lymphoproliferative disorders (EBV-PTLD) in 263 unrelated donor umbilical cord blood transplant recipients.” Blood 96, no. 11 (November 16, 2000): 206A-206A.

Scholars@Duke

Kurtzberg, J., P. L. Martin, P. M. Szabolcs, R. P. Howrey, T. A. Driscoll, C. E. Stevens, and P. Rubinstein. “Outcomes of unrelated umbilical cord blood transplantation in 158 pediatric patients consecutively transplanted at a single institution using cord blood units from a single bank.” Blood 96, no. 11 (November 16, 2000): 206A-206A.

Scholars@Duke

Pages